SCHEMBL4480988

SCHEMBL4480988

CC(O)CNc1nc(Oc2ccc(F)cc2F)nc2c1c(-c1ccccc1Cl)nn2CO

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 2/20 0.34
MAPK14 Q16539 3/20 0.34
PDE2A O00408 1/20 0.33
TRPA1 O75762 1/20 0.33
DGAT2 Q96PD7 5/20 0.32
CTSA P10619 1/20 0.32
RPS6KA4 O75676 1/20 0.32
MAPK8 P45983 1/20 0.32
MAPK9 P45984 1/20 0.32
CSNK1E P49674 1/20 0.32
RPS6KA3 P51812 1/20 0.32
MAPK10 P53779 1/20 0.32
MAPK11 Q15759 1/20 0.32
NLK Q9UBE8 1/20 0.32
MET P08581 4/20 0.31
AXL P30530 4/20 0.31
TYRO3 Q06418 4/20 0.31
MERTK Q12866 4/20 0.31
BRD4 O60885 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13672547 1.00 PDE10A (0.34) PDE10AMAPK14PDE2ATRPA1DGAT2
SCHEMBL4755290 0.91 FABP3 (0.36) MAPK14DGAT2CTSA
SCHEMBL4474346 0.89 DGAT2 (0.33) PDE10AMAPK14DGAT2CTSAMET
SCHEMBL13672548 0.89 DGAT2 (0.33) PDE10AMAPK14DGAT2CTSAMET
SCHEMBL13672572 0.88 DGAT1 (0.34) PDE10AMAPK14DGAT2METAXL
SCHEMBL4491581 0.88 MAPK14 (0.41) PDE10AMAPK14PDE2ATRPA1DGAT2
SCHEMBL4479724 0.87 FABP3 (0.37) DGAT2CTSAMETAXLTYRO3
SCHEMBL4480138 0.87 FABP3 (0.37) DGAT2CTSAMETAXLTYRO3
SCHEMBL4484559 0.85 MAPK14 (0.46) PDE10AMAPK14DGAT2MAPK8MAPK9
SCHEMBL4481511 0.84 PDE10A (0.33) PDE10ADGAT2METAXLTYRO3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7608603-B2 Substituted pyrazolo[3,4-D]pyrimidines as p38 MAP kinase inhibitors ROCHE PALO ALTO LLC (US) 2009-10-27 US claimed
US-7608603-B2 Substituted pyrazolo[3,4-D]pyrimidines as p38 MAP kinase inhibitors ROCHE PALO ALTO LLC (US) 2009-10-27 US disclosed
EP-1919914-A2 P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2008-05-14 EP disclosed
US-20070049597-A1 p38 MAP kinase inhibitors and methods for using the same ROCHE PALO ALTO LLC 2007-03-01 US disclosed
WO-2007023115-A2 P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049597-A1 p38 MAP kinase inhibitors and methods for using the same MAPK1, MAPK9, MAPK3 PDE10A 1976/4885MAPK14 22/4885PDE2A 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.